Collegium Pharmaceutical (COLL) Interest Expenses (2015 - 2026)

Collegium Pharmaceutical has reported Interest Expenses for 11 years, with the latest figure at $19.5 million in Q2 2026.

• On a quarterly basis, Interest Expenses fell 4.61% year-over-year to $19.5 million in Q2 2026; TTM through Jun 2026 was $76.4 million, a 7.12% decrease from a year earlier, with the FY2025 full-year figure at $82.3 million, up 11.27% from the prior year.
• Interest Expenses was $19.5 million for Q2 2026 at Collegium Pharmaceutical, up from $15.9 million in the prior quarter.
• The five-year high for Interest Expenses was $22.7 million in Q4 2024, with the low at $5.8 million in Q1 2022.
• Average Interest Expenses over 5 years is $18.8 million, with a median of $19.4 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Interest Expenses surged 332.52% in 2022, then fell 28.71% in 2024.
• Over 5 years, Interest Expenses stood at $20.6 million in 2022, then decreased by 6.29% to $19.3 million in 2023, then climbed by 17.49% to $22.7 million in 2024, then fell by 14.84% to $19.3 million in 2025, then advanced by 1.18% to $19.5 million in 2026.
• The last three Interest Expenses figures came in at $19.5 million (Q2 2026), $15.9 million (Q1 2026), and $19.3 million (Q4 2025), per Business Quant data.